Physicians at Massachusetts General Hospital’s Corrigan Minehan Heart Center recently marked a significant milestone by becoming the first team in New England to perform a transcatheter mitral valve replacement in a non-calcified mitral valve, a minimally-invasive procedure for patients with mitral valve regurgitation.
“The importance of replacing this valve without patients having to undergo a full, open-heart procedure can’t be overstated.”
The disease – which can cause patients to feel symptoms like shortness of breath and fatigue – occurs when blood flows back through the diseased valve to the atrium of the heart. Statistics show 1 in 5 patients age 70 and older are affected by this condition and, if left untreated, it can lead to heart failure. Traditionally, patients receive replacement valves through open-heart surgery.
“The importance of replacing this valve without patients having to undergo a full, open-heart procedure can’t be overstated,” says Jonathan Passeri, MD, co-director of the Mass General Heart Valve Program. “Patients spend much less time in the operating room, don’t have to be put on a heart-lung machine and, we hope, will recover much faster.”
An Exciting and Hopeful Pace
The procedure is performed by making a small incision between the ribs, inserting a catheter through the bottom of the left ventricle into the mitral position. The team – comprised of an interventional cardiologist, a cardiac surgeon, an echocardiographer and an anesthesia specialist – then inserts the replacement valve. The operation can be completed in less than an hour compared with traditional open-heart surgery which may take several hours.
The Mass General procedure is part of the APOLLO trial, a national study to analyze the effectiveness of the new synthetic valve administered via catheter versus open-heart surgery. Participants for the trial are adults experiencing moderate to severe mitral valve regurgitation who are candidates for traditional valve replacement.
“The pace at which this field is accelerating is exciting for us and hopeful for patients,” says Serguei Melnitchouk, MD, cardiac surgeon, co-director of the Heart Valve Program and co-principal investigator of the trial.
Immeasurable Patient Benefit
While the procedure is a notable event in the treatment of heart valve disease, it is not the first time the Mass General Heart Valve Program has made history. Ten years and one day before this procedure, a team of Mass General specialists were the first in New England to perform a transcatheter aortic valve replacement.
“We’ve seen the impact that minimally-invasive aortic valve replacements have had on patients for more than a decade,” Dr. Melnitchouk says, “and the possibility of replicating that success with the mitral valve, which is significantly more difficult, is inspiring.”
Ignacio Inglessis-Azuaje, MD, interventional cardiologist, and co-principal investigator of the APOLLO trial, says, “We are so fortunate to have such an amazing team of caregivers here at MGH. From the physicians to the nurses – both in the operating room and on the floors – you can’t ask for a more talented and collaborative team. The benefit to the patient is immeasurable.”
For more information on how you can support the Corrigan Minehan Heart Center, please contact us.
This article first appeared in MGH Hotline.